San Francisco biotech General Proximity Bio has secured notable early-stage investment for its induced-proximity medicine platform. The company emerged from stealth in January 2025 with $16 million in seed funding led by Felicis Ventures, alongside Y Combinator, age1, and other investors. It subsequently closed an oversubscribed $12 million pre-Series A round, attracting strategic investment from Daewoong Pharmaceutical and FreeMind Investments. General Proximity also received non-dilutive support through grants from ARPA-H and the National Cancer Institute. The platform targets proteins traditionally considered difficult to drug, focusing on cancer, cardiometabolic disease, neurodegeneration, and longevity. The company remains preclinical with no public IND filing or lead asset. Scientific challenges in proximity-based drug design include selectivity, pharmacokinetics, oral delivery, and off-target effects. General Proximity is pursuing a platform approach rather than developing a single near-term product.

Daewoong Pharmaceutical has invested in US biotech firm General Proximity alongside venture capital fund Freemind Investment to collaborate on new drug development. The investment amount was not disclosed. The partnership aims to secure "induced proximity" technology, a next-generation drug development method that regulates protein function by bringing disease-related proteins and regulatory proteins together. This approach differs from conventional methods that required drugs to fit precisely into specific binding sites, potentially expanding treatment options for previously inaccessible proteins. Founded in 2019, General Proximity possesses a platform for discovering induced proximity therapeutics based on Effectome scanning technology. The company is developing new drug pipelines in oncology, cardiovascular and metabolic diseases, and neurodegenerative diseases.